Neurocrine Biosciences, Inc. - Common Stock (NBIX)

Neurocrine stock gains as Q1 EPS beats estimates; Ingrezza sales climb 8% YoY with record new patients and strong analyst price target hikes.

The company reported a strong start for its newest drug, Crenessity, which treats a hormonal disorder involving the adrenal glands.

CEO Kyle Gano highlighted record new patient starts for Ingrezza and noted positive early response to the launch of Crenessity, positioning the company for sustained growth.

Neurocrine Biosciences Inc (NASDAQ:NBIX): A Strong Affordable Growth Stock

Top performers last week: ServiceTitan, Summit Therapeutics, YPF, Eli Lilly, MicroStrategy, America Movil, Ericsson, Insmed, Diamondback, Neurocrine Biosciences.

Physician survey shows high uptake of Neurocrine Biosciences' Crenessity for patients with CAH.

Based on Fundamental Analysis it can be said that NASDAQ:NBIX is a growth stock which is not overvalued.

Discover NEUROCRINE BIOSCIENCES INC, an undervalued stock. NASDAQ:NBIX showcases solid financial health and profitability while maintaining an appealing valuation.

Based on a technical and fundamental analysis of NASDAQ:NBIX we can say: NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—Positioned as a High-Growth Stock, Ready for a Potential Breakout.

NASDAQ:NBIX is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced.

NEUROCRINE BIOSCIENCES INC has a stellar value proposition. NASDAQ:NBIX not only scores well in profitability, solvency, and liquidity but also maintains a very reasonable price point.

NASDAQ:NBIX is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced.

Skyworks Solutions, Estee Lauder, Venture Global, Neurocrine Biosciences, Moderna, Illumina, IDEX Corporation, PTC Inc, PayPal Holdings, Skechers U.S.A. and Avantor were worst performers, fell up to 25%.

Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while revenue slightly missed estimates.